RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
THGRX
Price
$34.72
Change
-$0.18 (-0.52%)
Updated
Sep 20 closing price
Ad is loading...

RPTIX vs THGRX

Header iconRPTIX vs THGRX Comparison
Open Charts RPTIX vs THGRXBanner chart's image
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
Thornburg Small/Mid Cap Growth R5
Price$34.72
Change-$0.18 (-0.52%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
RPTIX vs THGRX Comparison Chart
Loading...
VS
RPTIX vs. THGRX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPTIX is a StrongBuy and THGRX is a Buy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. THGRX (276M). RPTIX pays higher dividends than THGRX: RPTIX (0.18) vs THGRX (0.00). RPTIX was incepted earlier than THGRX: RPTIX (9 years) vs THGRX (19 years). THGRX is a more actively managed with annual turnover of: 57.56 vs. RPTIX (21.70). THGRX has a lower initial minimum investment than RPTIX: THGRX (0) vs RPTIX (500000). THGRX annual gain was more profitable for investors over the last year : 25.21 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. THGRX (-19.91).
RPTIXTHGRXRPTIX / THGRX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years19 years-
Gain YTD9.12715.73358%
Front LoadN/AN/A-
Min. Initial Investment5000000-
Min. Initial Investment IRAN/AN/A-
Net Assets31.4B276M11,377%
Annual Yield % from dividends0.180.00-
Returns for 1 year14.8125.2159%
Returns for 3 years-13.57-40.5633%
Returns for 5 years15.09-19.91-76%
Returns for 10 yearsN/A24.13-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp